Objectif
The GDAPIV project will deliver a next generation of genomics analysis and visualization web platform GenX that will enable bioinformatics experts (IT experts supporting life scientists) to rapidly construct diverse visual interactive web applications for researchers working in the life sciences and biomedical fields (life scientists).
GenX will enable the researchers or biomedical experts to proactively control the bioinformatics data analysis and exploration steps when validating research hypotheses. It will eliminate the need for continuous involvement of bioinformatics expert in every step of data analysis procedures, thus greatly facilitating the speed and simplicity of experimental or diagnostics processes. Even more importantly, GenX project will provide the researcher with instant insight into the genome sequence data and related downstream analyses, allowing to interactively modify and test the research hypothesis and assess them in real time, as they arise. This will significantly save time and resources, and it will disrupt the approach to the life science research and related services.
With the GDAPIV project, we strive towards “riding the wave” of the genomics revolution – exploiting the Next-Generation Sequencing opportunity and significant expansion of sequencing machine owners (biotech, clinics, pharmaceuticals, basic research, commercial sequencing facilities) – all of these are potential customers, especially considering the pitfalls of existent solutions available to the commercial sector.
The purpose of GDAPIV project is:
- to create and test GenX prototype and
- to explore business models that exploit the project’s commercial potential to the fullest.
Champ scientifique
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- social sciencesmedia and communicationsgraphic design
- natural sciencescomputer and information sciencesdata sciencebig data
- social scienceseconomics and businessbusiness and managementbusiness models
- engineering and technologyindustrial biotechnologybiomaterialsbiofuels
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
1000 LJUBLJANA
Slovénie
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.